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INTRODUCTION
There has been an increased international will and 
commitment to expand programmes for providing 
highly active anti-retroviral therapy (HAART) to those 
who need them. These include the ‘3x5’ initiative 
by the World Health Organisation (WHO), the 
Global fund for AIDS, TB and malaria, and the U.S. 
government’s presidential emergency plan for AIDS 
relief (PEPFAR). All these have resulted in increased 
access to HAART for HIV infected individuals in 
resource-constrained settings. However, few studies 
have addressed the area of adverse drug reactions 
(ADRs) in these settings (1, 2).
 Most of the published studies have been from 
developed countries which have advanced ADRs 
monitoring and reporting systems. In Kenyatta 
National Hospital (KNH), as in most other parts of 
the country, the emphasis has been on trying to put as 
many eligible patients as possible on HAART. Being 
a resource constrained facility, there have been few 
ADR studies.
 Monitoring of ADRs is particularly important 
for anti-retroviral drugs since many are licensed on 
the basis of limited safety data and they are likely to 
be used in combinations untested in pre-marketing 
studies.
 Further, individuals with HIV infection 
are often treated with many other drugs for the 
prevention and treatment of opportunistic infections 
and there are a number of potential interactions 
with anti-retroviral drugs (3).
 In developed countries, liver-function tests, 
and serum creatinine and lipid levels are routinely 
used in assessing patients for ADRs (1). However, 
countries with limited resources lack the laboratory 
infrastructure to perform these assays routinely.
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ABSTRACT
Background: There has been an increased access to anti-retrovirals in resource-
constrained settings. However, few studies have addressed the area of adverse drug 
reactions in these settings.
Objective: To determine the prevalence of adverse drugs reactions in HIV-infected 
persons receiving anti-retrovirals.
Design: A retrospective cohort study.
Setting: Kenyatta National Hospital, Comprehensive Care Centre.
Subjects: Adult patients receiving anti-retroviral drug during the four year period 
between January 2003 and December 2006.
Main outcome measures: The primary outcome was a documented adverse drug reaction 
after exposure to antiretrovirals.
Results: Systematic random sampling was used to pick 350 patients’ ﬁles. There were 
219 recorded adverse drug reactions in 170 (48.6%) patients (some patients had more 
than one adverse drug reaction). Peripheral neuropathy was the most common adverse 
drug reaction with a prevalence of 28.9% followed by lipid abnormalities at 14.3%.
Conclusion: This study indicates a high prevalence of adverse drug reactions 
among HIV/AIDS patients on anti-retroviral therapy at Kenyatta National Hospital, 
Comprehensive Care Centre.
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With increased access to HAART, it is important 
that developing countries should undertake further 
clinical research to optimise guidelines for the care of 
HIV-infected patients in local situations. In an effort to 
address the above needs, a consensus conference was 
held to discuss priorities for anti-retroviral therapy 
research in Zambia, one of the world’s most heavily 
HIV-afﬂicted nations. There was global consensus that 
anti-retroviral clinical trials in resource-constrained 
countries were possible, and the capacity for such trials 
should be developed further in Africa (4).
 The World Health Organisation deﬁnes an 
adverse drug reaction (ADR) as “A response to a 
drug which is noxious and unintended, and which 
occurs at doses normally used in humans for 
prophylaxis, diagnosis or therapy of disease, or for 
the modiﬁcation of physiological function” (5,6). This 
deﬁnition excludes therapeutic failures, intentional 
and accidental poisoning and drug abuse. Using this 
conservative deﬁnition avoids overestimating the 
ADR prevalence.
 All anti-retroviral drugs have both short-term 
and long-term ADRs. The risk of speciﬁc ADRs 
varies according to speciﬁc drug, class of drug and 
individual susceptibility.
 A better understanding of the ADRs of anti-
retroviral agents is of interest to optimise therapy in 
HIV infected patients (7).
MATERIALS AND METHODS
This hospital based retrospective cohort study was 
carried out at the Kenyatta National Hospital (KNH) 
Comprehensive Care Centre (CCC).
Data collection and analyses: Around 4000 patients 
were initiated on HAART between January, 2003 
and December, 2006. The records were arranged in 
order of HAART initiation date and every ﬁfth ﬁle 
was examined for possible inclusion. Of the 831 ﬁles 
examined, 350 met the inclusion criteria for the study. 
These were all adult patients (≥18 years at the time of 
diagnosis) with HIV/AIDS initiated into HAART at 
the CCC in KNH during the four year study period 
whose baseline laboratory results were available in 
the ﬁles and whose baseline laboratory results and 
initial clinical examination did not indicate a pre-
existing ADR related condition.
 The sampled ﬁles were reviewed to pick out 
clinician records of any of the speciﬁed six ADRs, 
patient characteristics and baseline laboratory tests. 
Relevant data were entered into a pre-designed data 
collection form before transfer into the Statistical 
Package for Social Sciences (SPSS 13.0) database for 
analysis.
Case deﬁnitions: The primary outcome was having 
a documented ADR after exposure to HAART. 
The cases were deﬁned according to the guidelines 
contained in the Kenya National Clinical Manual for 
ART providers (8), which mainly follows the criteria 
used by the AIDS Clinical Trials Group (ACTG) (9). 
Peripheral neuropathy (PN). Patients were considered 
to have experienced peripheral neuropathy if they 
presented with any of the symptoms ranging from 
mild tingling sensation, numbness, muscle weakness 
and pain to severe incapacitating pain and inability 
to walk (8).
Lipid abnormalities: Lipid abnormalities (LA) were 
recorded if the patient had a hump on the back, loss 
of facial fat, thinning of arms or central fat deposition 
(8). Serum lipid proﬁles were not used in deﬁning 
lipid abnormalities because records of lipid proﬁles 
for both before and after the initiation into HAART 
were not available for most ﬁles.
Hepatoxicity: A patient was recorded as having 
hepatoxicity if the levels of alanine aminotransferase 
(ALT) rose above 40 IU/L (9). Severe liver toxicity 
(grade 3 or 4) was deﬁned as a greater than ﬁve 
fold increase in levels of ALT and/or aspartate 
aminotransferase (AST) above the upper limit of 
normal (ULN), following the criteria used by the 
AIDS Clinical Trials Group (ACTG) (9).
Haematological toxicity: Patients were considered to have 
haematological toxicity if the level of haemoglobin 
(Hb) was less than 8g/dl or neutrophils less than 1000 
/mm3 after exposure to the drugs (8).
Skin rash: Patients were considered to have skin 
rashes if there were records of the patient having skin 
conditions ranging from mild cases of erythema and 
pruritus to severe mucous membrane involvement 
(e.g., Stevens-Johnson syndrome) (8).
Renal abnormalities: Renal abnormalities were recorded 
if the renal function tests showed rising levels of 
serum creatinine above 150 μmol/l after exposure 
to the drugs (8).
Data quality control: Before the full study, the 
investigator consulted the primary clinicians 
involved in the direct patient care at the KNH, CCC 
to understand how they documented ADRs and the 
terms which they used to describe the ADRs in the 
CCC. This helped in the design of an appropriate 
data collection form. The reliability of the data were 
enhanced by having a second person (peer) to ﬁll 
a ‘data reliability form’ by randomly sampling one 
out of every ten ﬁles studied by the investigator. 
The data reliability form was exactly the same as 
the data extraction form except that it was ﬁlled by 
a different person. The two were then compared and 
any discrepancies addressed.
560 EAST AFRICAN MEDICAL JOURNAL December 2009 
RESULTS
A total of 831 ﬁles were retrieved from the KNH, 
CCC records. Four hundred and eighty one (57.9%) 
of the retrieved ﬁles were excluded because: 34.5% 
had been on HAART for less than a year, 8.4% were 
patients who had started HAART elsewhere before 
40 years. Males were generally older than the females 
(median age 42 vs 39, p = 0.003) (Figure 1).
HAART regimens dispensed: All patients on treatment 
were started on protease inhibitor-sparing regimens 
with 92% on Stavudine (D4T) based regimens. The 
most common regimen was the stavudine, lamivudine 
and nevirapine combination which accounted for 
56% of the regimens used (Figure 2).
Figure 2
Categories of HAART regimens among study population prevalence of ADRs
Prevalence of ADRs: At least one ADR was reported in 
48.6% of the patients. Some patients reported more 
than one ADR with 1.7% presenting with three ADRs 


























transferring into KNH, hence had no baseline 
records, 7.3% were below 18 years of age, 4.7% 
date of starting HAART was not indicated, 1.8% 
had incomplete HAART records and 1.1% started 
HAART before January 2003. The remaining 350 
patients were enrolled into the study.
 The study participants had a median age of 40 
(range 23 – 65) years, 57% were female, 52% were 
married and 91% had some formal education. The 
median CD4 count was 123 (range 1 – 904) while 
the median time on HAART was 32 (range 12-56) 
months.
Age and gender distribution of the sample: The majority 
of patients (79.4%) were in the 31-50 year age group. 
There was a higher proportion of males aged above 
40 years (57%) compared to the females (40.4%) above 
Figure 1
Age and gender distribution of the study population
(years)
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Figure 3
Prevalence of ADRs in the study participants
Prevalence of speciﬁc ADRs: Peripheral neuropathy was 
the most common ADR with a prevalence of 28.9% 
followed by lipid abnormalities at 14.3%. (Figure 4).
Time to development of ﬁrst ADR: The median time to 
development of ﬁrst ADR ranged from two months 
for rashes to 29 months for lipid abnormalities. First 
cases of most ADRs were seen early except for renal 
and lipid abnormalies whose ﬁrst cases occurred in 
the second year of HAART (Table 3). Rashes and renal 
abnormalities had a narrow range. A wide range was 
seen with the other ADRs (Table 1).
Trends/Distribution of ADRs over time: Prevalence of all 
the ADRs generally increased with time on HAART. 
The prevalence of at least one ADR increased from 
29% in the ﬁrst 12 months to 58% by the 48th month. 
There seemed to be a plateau phase after 48 months 
on HAART (Figure 5).
Figure 4
Prevalence of speciﬁc ADRs in the study participants
Table 1
Time (in months) to development of ﬁrst ADR
 Rashes Haematological Peripheral Hepatoxicity Renal Lipid
  disorders neuropathy  abnormalities abnormalities
Median 2 4 8 11.5 18.5 29
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Figure 5
Prevalence of ADRs with increasing time on HAART (categorised in 12 month intervals)
DISCUSSION
The current study is one of the few ADR studies 
carried out in resource-limited settings. The results 
suggest a high prevalence of ADRs among patients on 
HAART and hence need for their closer monitoring 
and management.
 Of concern in this study is that 287 patient ﬁles 
perused (34.5%)  had to be excluded because the patients 
stayed on HAART for less than a year. The high drop 
out from the programme in the ﬁrst year needs to be 
investigated as some of these withdrawals may be due 
to intolerable ADRs or disease related deaths.
 In this cohort females were more (57%) and 
relatively younger than their male counterparts 
(median age of 39 vs 42 and mean 40 vs 43, p=0.004). 
Fifty seven per cent of males were aged above 40 years 
compared to 40.4% females. This compares well with 
the national estimates that there are more of younger 
HIV-infected women than men in Kenya (10).
 The most common regimen was stavudine, 
lamivudine plus nevirapine. This is in keeping 
with the national guidelines to use this regimen as 
the standard ﬁrst line HAART (8). The high (95%) 
compliance to the national guidelines on HAART 
initiation serves to demonstrate the potential of well 
written guidelines to standardise pharmaceutical 
care of complex disease conditions like HIV/AIDS 
in resource-limited settings.
Forty nine per cent of patients developed at least one 
ADR in this cohort; previous studies have reported 
antiretroviral toxicity in 11 - 76% of their cohorts, but 
comparison between studies is difﬁcult as a result of 
differences in reporting of ADRs; studies may report 
overall ADRs, severe ADRs only, treatment-limiting 
ADRs, or laboratory diagnosed ADRs only (11-13). 
Nevertheless, this prevalence of ADRs compares 
well with other studies in resource-limited settings. 
For example, in an observational study carried out 
between 2003 and 2004 in rural Uganda on 1029 adult 
HIV/AIDS patients on HAART, ADRs were found 
in 40% of the patients (14). This study was similar 
to our study in that it reported clinically apparent 
ADRs only.
 Our results compare well with those obtained 
in a prospective study conducted from 2001 to 
2003 to assess factors associated with ADRs among 
individuals initiating HAART at two public referral 
HIV/AIDS centres in Brazil which reported 
occurrence of at least one ADR in 34.5% of the 397 
patients although they did include patients who had 
been on HAART for less than one year (12).
 However, our results differed slightly from those 
obtained in a study carried out in St. Mary’s Mission 
Hospital in Nairobi, from September 2004 until August 
2006 (15). The study which involved a total of 1286 
patients reported that HAART related clinical toxicities 
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were conducted in the same town, the difference in 
results could be due to the different methodology, 
duration of study and population characteristics. While 
the St Mary’s study was a longitudinal observation of 
clinical, immunologic and treatment parameters of 
all HIV-infected adult patients initiated on HAART 
with at least one follow-up visit, the KNH study was 
retrospective and included only those patients who 
had been on HAART for at least a year. Moreover, 
the St Mary’s study covered two year duration unlike 
our study which followed patients for up to ﬁve 
years. The longer follow up in our study may have 
contributed to the higher prevalence observed as a 
result of accumulation of ADRs with time.
 The six ADRs of interest in our study differed 
markedly in their prevalence and time of occurrence. 
This suggests that clinicians should look out carefully 
for ADRs in each and every visit to avoid more harm 
occurring to the patients.
 The prevalence of peripheral neuropathy was 
28.9% in our study making it the most common ADR. 
This was consistent with ﬁndings from several other 
studies in resource-limited settings. In the two studies 
carried out at rural Uganda and St Mary’s hospital 
in Nairobi, peripheral neuropathy was reported 
most frequently with a prevalence of 36% and 20.7% 
respectively (14,15). Peripheral neuropathy was also 
the most common ADR in a cross-sectional study 
involving 720 patients in a large teaching hospital 
in Malawi (16).
 Lipid abnormalities were the second most 
common ADR with a prevalence of 14.3%. This 
compares well with a combined retrospective and 
prospective study conducted on 83 adult HIV-
treatment-naïve patients in Thailand (17) which 
reported that 16.8% had symptoms of lipodystrophy 
within two years of treatment with a combination 
of stavudine, lamivudine plus nevirapine, the most 
common HAART regimen in our study.
 However, the results from our study are different 
from those obtained in 409 patients starting WHO 
recommended ﬁrst-line HAART regimens in Rwanda 
which reported a high prevalence of lipodystrophy 
of 34% (18). Whilst ours was a purely retrospective 
study, the Rwanda study subjected the patients to 
a standardised case deﬁnition-based questionnaire 
and clinical assessment. This may have made it much 
easier to pick ADRs. The Rwanda study also had a 
high proportion of patients who had been on HAART 
for longer than our patients. It has been observed that 
the risks of lipid abnormalities increase with time on 
HAART.
 A cross-sectional study at KNH between 
January and April 2006 reported a high prevalence 
of dyslipidemia of 63.1% (19). This study differs 
from the current study in that it involved doing lipid 
proﬁles for all patients unlike in the current study 
which recorded clinically apparent lipid abnormalities 
only. This highlights the need for routine laboratory 
monitoring of all the patients at regular intervals in 
order to detect any abnormalities before they are 
clinically apparent.
 The prevalence of rashes in our cohort was 
low (12.9%); in contrast, a prospective study on 202 
patients in Thailand reported rash in 34% of patients 
on nevirapine or efavirenz (20). This is not surprising 
because a reduced occurrence of rashes has been noted 
in Africa for other medications like cotrimoxazole 
(21). Our ﬁndings are similar to those obtained in 
several other studies in Africa; the study in rural 
Uganda also reported a low frequency of rash (6%) 
(14) while rashes occurred in approximately 3.7% of 
patients in the St Mary’s (Kenya) study (15). This may 
partly be explained by the fact that it is much harder 
to see rashes on the dark skin of Africans compared 
to the lighter skin of Asians.
 Hepatoxicity associated with nevirapine use has 
been reported with varying frequency in many studies 
of HAART-related toxicity in resource-limited settings  
(22). However, though several antiretrovirals have 
been reported to cause fatal acute hepatitis, most 
often they only cause an asymptomatic elevation 
of ALT (23). In our study, hepatoxicity occurred in 
approximately 4% of patients, which is higher rate than 
among several cohorts in resource-limited settings. 
The Uganda and Kenya studies reported a frequency 
of acute hepatitis of 0.5% and 0% respectively (14, 15). 
The difference could be because these two studies 
reported only acute cases. The difference may also 
be attributed to the low use of laboratory diagnosis 
of hepatoxicity and other ADRs in resource-limited 
settings. However, our results compare well with 
those of a retrospective study involving 3154 patients 
at a tertiary HIV care referral centre in South India 
which reported hepatitis in 3.5% of patients (24).
 The prevalence of haematological disorders of 
2% in our study compares well with other studies in 
resource-limited settings; a prospective cohort study 
on 169 patients in Cameroon found that anaemia 
was rare with a prevalence rate of 4% and 6% for 
zidovudine and stavudine containing regimens 
respectively (25). The study in South India reported 
that clinically signiﬁcant anaemia was observed in 
5.4% of patients (25), while the study in rural Uganda 
reported an even lower frequency of 0.4% (15).
 The ﬁndings in this study that the occurrence 
of lipid abnormalities differed markedly from that 
of rashes in that, while the ﬁrst cases of rashes were 
reported within a few days after HAART initiation, 
no cases of lipid abnormalities were seen before 
eleve months of HAART. This suggests the need for 
frequent and early monitoring for rashes while the 
late occurrence of lipid abnormalities suggests that 
clinicians should watch out for them on all patients 
who have been on treatment for duration of about 
one year or more.
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 Our study was limited by potential of either 
over or under-reporting of ADRs in patient ﬁles. This 
being a retrospective study, it relied on pre-recorded 
information which may have been incomplete or 
inaccurate. Also, most of the recorded ADRs were 
those which were clinically apparent. ADRs that 
required laboratory diagnosis may have been missed 
because tests were not done routinely due to cost 
limitations.
 In conclusion, this study indicates a fairly 
high prevalence of ADRs among HIV/AIDS 
patients on HAART at Kenyatta National Hospital 
Comprehensive Care Centre. This being among the 
ﬁrst few studies on ADRs of antiretrovirals in Kenya, 
further research is required. This is important because 
of the rapidly expanding access to antiretrovirals, the 
lack of regular laboratory monitoring in these settings 
and the wide range of ADR prevalence reported in 
the few studies done so far.
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